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Rheumatoid arthritis (RA) is an autoimmune disease that is characterized by persistent intense immunological activity, local destruction of bone and cartilage, and a variety of systemic manifestations (1) . Although the pathogenesis is yet to be fully resolved, the T helper (Th)l/Th2 response is known to play an important role in the development of RA (2) . Adult patients with active RA have been shown to have a dominant Th1 cell-mediated immune response (Th1 advantage), as reported in experimental, clinical and epidemiological studies in vivo and in vitro (1, 2) . In addition, inducing a Th2-type response was found to be beneficial for the treatment of RA in an in vivo rat model induced by type Ⅱ collagen, while a drug-induced Th2 response was able to inhibit the inflammation observed in RA induced by excessive Th1 responses in vitro (2) . To date, studies investigating the balance of the Th1/Th2 response in peripheral blood mononuclear cells (PBMCs) for the clinical treatment of RA are limited, and reliable conclusions are yet to be established.
Children aged <16 years suffering from RA are classified as having juvenile RA (JRA), which is now known as juvenile idiopathic arthritis (JIA). This condition is clinically and genetically distinct from that observed in adult patients (3) . In previous studies on children with JIA, the majority of cases have presented with a dominant Th2 cell-mediated immune response (Th2 advantage) (4, 5) . In addition, the longer the course of the disease, the more significant the Th2 response (5) . Furthermore, treatment with Th1-type cytokines, such as interferon (IFN)-γ, may be useful for the control of JIA (6) . However, a type 1 phenotype of synovial fluid T cells has also been identified in patients with JIA, suggesting a high IFN-γ to interleukin (IL)-4 ratio in the synovial fluid, which indicates that specific activation events have occurred in the synovial T cells that may differ from PMBC T cells (7) .
In addition, longitudinal studies in human patients with RA have revealed that the production of Th1/Th2-type cytokines in different stages, particularly in the early and late stages, are not the same, which suggests that there may be a shift in the Thl/Th2 balance at different development stages of RA. A Th2 response dominates in the PBMCs at early stages of RA, while long-term chronic RA exhibits a Th1 dominant response (8) . Patients with early inflammatory arthritis, who subsequently developed RA, had a distinct but transient synovial fluid cytokine profile. The levels of type 2 cytokines, such as IL-4 and IL-13, were significantly elevated in these patients within 3 months after symptom onset, as compared with the early arthritis patients who did not develop RA. In addition, this cytokine profile was not present in patients with established RA. By contrast, patients with non-rheumatoid persistent synovitis exhibited elevated levels of IFN-γ at the initiation of the disease, which suggested that early synovitis destined to develop into RA may be characterized by a distinct and transient synovial fluid cytokine profile (9) . However, in an adult patient with active RA, a dominant Th1 response was initially observed in the synovium, while a dominant Th2 response was observed in the PBMCs. Subsequently, a Th0 and Th1 response became dominant in the synovium, which was associated with disease inflammation (10) .
Therefore, whether the Th1 or Th2 response is dominant in RA may depend on a variety of factors, including the age of the patients (JIA or RA), the stage of RA (early or late) and where the condition is located (PBMCs or synovial fluid). However, the mechanisms underlying the mediation of the imbalance in the Th1/Th2 response, particularly during the early stages of RA, remain unclear. In our clinical experience (data not published), the majority of newly diagnosed JIA cases were in the early stage, while the diagnosis of adult RA cases occurred predominantly during the interim or late stage of the disease. Based on these observations, a Th2 imbalanced response may be more important in the early stage of RA.
Role of basophils in the Th1/Th2 response
In recent years, research into the effector functions and immunoregulatory effects of basophils has made considerable progress with marked achievements (11). Falcone et al described the current insights into the roles of basophils in allergic responses and innate immunity (12) . Karasuyama et al referred to basophils as a neglected minority that have gained a new respect following recent immunological studies (13) .
The major immunoregulatory role of basophils in the regulation of the Th1/Th2 balance is the induction of Th2 immunity (14) . Basophils are able to induce Th2 immunity by primarily secreting key Th2-inducing cytokines, namely IL-4 and thymic stromal lymphopoietin (TSLP), and by functioning as professional antigen presenting cells. Basophils are an efficient producer of Th2-type cytokines, such as IL-4 and IL-13, which are able to enhance the differentiation of Th0 into Th2 and inhibit the differentiation of Th0 to Th1 (15, 16) . As such, following stimulation with allergens and innate IgE-dependent triggers or other activation methods, a novel immunoregulatory role of basophils has been identified in the regulation of the Th1/Th2 balance in vitro and in vivo (17) . In addition, TSLP produced by basophils in the lymph nodes is important for the initiation of Th2 differentiation in vivo and in vitro (18) . In a T cell-independent pathway, basophils induce an isotype switch toward IgE in human tonsillar B cells (19) , which subsequently enhances the Th2-type humoral immune response (18) . Therefore, basophils are able to regulate the Th1/Th2 balance by enhancing Th2 immunity, and may participate in the pathogenesis of various autoimmune diseases.
Basophils may play a key role in the development of RA
A study that included 800 adult patients with RA found that the number of peripheral basophils was significantly decreased, although the cells were activated (20) . In addition, the results of our study exhibited a similar trend in adult RA patients (21) . However, the reason for the decreased number of peripheral basophils remains unclear, and the role of the decreased level of activated basophils in the development of RA, which is Th1 response dominant, requires further investigation.
A number of inflammatory effector cells, including macrophages and lymphocytes, have been observed to infiltrate into inflammatory sites in RA, such as synovial joint tissues. Furthermore, in animal models, such as guinea pigs, basophils have been shown to infiltrate into tissues during cutaneous hypersensitivity responses (cutaneous basophil hypersensitivity) (22, 23) . Basophil infiltration has also been observed in allergen-induced late-phase cutaneous responses in human atopic subjects (24) , and has been implicated in allergic human diseases (25) . Previous observations in mice have clearly demonstrated that basophils are essential initiator cells of IgE-mediated chronic allergic inflammation (26) , and are capable of functioning as a source of IL-4 and contributing to Th2-type immunity (27) . An explanation for the concomitant recruitment of basophils may be due to the common expression of C-C chemokine receptor (CCR)3. Eotaxin 1 and 3, which are ligands of CCR3, are produced by several types of cell in response to Th2-type cytokines, such as IL-4 and IL-13.
In addition, basophils have been observed in the lymph node tissues of patients with systemic lupus erythematosus. Basophils may migrate to the lymph nodes due to the higher expression of the adhesion molecule, CD62L (28) . Therefore, it was hypothesized that basophils become activated following migration to the lymph nodes or local inflammatory tissue, where they are involved in the inflammatory response, subsequently leading to a reduction in the number of peripheral blood basophils, and thus participating in the pathogenesis of adult RA (Fig. 1 ).
Number and activation degree of peripheral blood basophils in JIA
Athreya et al (33, 34) reported that peripheral basophils were increased in absolute number and in percentage in 11 out of 16 patients with JIA. The increase was particularly significant in children with active polyarticular arthritis.
JRA is an autoimmune disease which mainly causes the inflammation of joints. For the purpose of improving the description and classification of several forms of JRA, ILAR (International League of Associations for Rheumatology) recently redefined the disease. The name of JRA was changed to JIA. Furthermore, the classification of JIA has been expanded to include two further conditions, spondyloarthropathy and psoriatic arthritis, which were not previously classified under JRA (35, 36) .
Mechanisms underlying periphery basophil activation in RA
Basophils are an important source of Th2-type cytokines. Basophils collected from humans and mice have been shown to rapidly secrete large quantities of IL-4, as compared with Th2 cells, in response to various stimulations, including signaling through the FcεRI (37) (38) (39) (40) . Moreover, upon IgE-receptor cross linking in basophils, a number of cell surface membrane antigens appear to be translocated from cytoplasmic membranes onto the cell surface (41) (42) (43) (44) (45) (46) (47) (48) . These upregulated cell surface membrane molecules include CD11b, CD13, CD63, CD107a, CD107b and CD203c (49) .
In addition, in RA patients, higher levels of IgE type antibodies, which primarily form immune complexes (47) and circulating immune complexes (IgE-CIC) containing IgE, can be detected in the peripheral blood and synovial fluid (51) (52) (53) . Furthermore, IgE-CIC-positive RA patients exhibit higher disease activity compared with negative patients (51) . IgE-CIC can activate inflammatory effector cells, such as mast cells, neutrophils and mononuclear cells (51, 55) , which subsequently promotes RA disease progression. These observations indicate that IgE immune complexes may mediate basophil activation in RA.
As reported, several animal models of arthritis are associated with a Th1 skew, and arthritis in such models can be ameliorated by therapeutic intervention aimed at restoring the Th1/Th2 balance (57) (58) (59) . However, further investigation of the potential function of basophils in restoring the Th1/Th2 balance in RA, particularly in the early stage of RA, may be a novel therapeutic strategy in RA and requires further investigation.
Basophils may be involved in the development of RA by affecting the Th1/Th2 balance, particularly in the early stages of RA. Therefore, targeting basophils may be a novel therapeutic strategy for the treatment of RA; however, further studies are required to confirm this. Autoreactive T and B cells trigger autoantibody production and CIC formation during RA, which may be mediated via activated basophils. These basophils may migrate from the blood into tissue sites, such as the lymph nodes, via the expression of CD62L, where they can interact with B and T cells, or inflammatory sites, via the expression of transcripts of CCR1, CCR2, CCR3, and CCR5 and CXCR1, CXCR2 and CXCR4, where they exert effector functions through the release of diverse, proinflammatory mediators (29) (30) (31) (32) . IL, interleukin; TSLP, thymic stromal lymphopoietin; BCMA, B cell maturation antigen; TACI, transmembrane activator and calcium modulator and cyclophilin ligand interactor; BAFF-R, B-cell activating factor receptor; TH, T helper; TCR, T-cell receptor; MHC, major histocompatibility complex; CCR, C-C chemokine receptor; CXCR, C-X-C chemokine receptor; TLR, Toll-like receptor; CIC, circulating antigen-antibody immune complexes.
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